Request ConsultationRetatrutide is an investigational drug that is being investigated by Eli Lilly and Company as a once-weekly drug for obesity and other metabolic diseases. Retatrutide is a novel triple hormone receptor agonist, which means that it targets the receptors of GIP, GLP-1, and glucagon. The drug is under study for its effect on body weight and blood glucose levels, as well as several complications arising from obesity. Retatrutide is applied via subcutaneous injections during the studies. As of September 2026, retatrutide has not received approval from any regulatory body and, therefore, cannot be called an approved prescription drug. Several successful phase 3 trials have been conducted by Lilly, and the company intends to apply for a Biologics License Application to the FDA in Q1 2027.
Important Warnings while taking Retatrutide
However, since retatrutide is still investigational, the full safety profile and risks associated with it have yet to be determined. It is not meant for purchase or use except as part of a clinical study under the auspices of Lilly. The company has warned against unauthorized products of retatrutide, which may have inaccurate levels of active compounds and other contaminants, outside of Lilly’s authorized clinical trials.
Adverse events involving the digestive tract similar to other incretin therapies have been documented in the studies conducted. Gastrointestinal symptoms such as nausea, diarrhea, and vomiting may happen especially when doses are gradually increased. Phase 3 studies employed dose escalation.
Retatrutide also causes significant variations in body weight and glucose levels, necessitating medical monitoring, especially for patients with diabetes or those on other antidiabetic medications. Research trials have shown improvements in both A1C and body weight among patients with type 2 diabetes.
Retatrutide is effective in stimulating three hormones and is undergoing clinical research. This means that medical experts are still examining the side effects, patient suitability, dosage, and safety of retatrutide. Patients should not mimic clinical trial dosages without being part of a medical study.
Things to consider before Retatrutide consumption
- Regulatory approval status
- Allergies
- Diabetes and blood glucose
- Gastrointestinal conditions
- Pancreatic or gallbladder problems
- Kidney or liver disease
- Pregnancy and breastfeeding
- Other medications
- Previous weight-loss treatments
- Eating and nutritional status
- Participation in a clinical trial
These aspects are significant due to the fact that the investigational nature of the drug means that it must be administered under an appropriate clinical trial or future approved treatment regimen. Diabetes patients and individuals on glucose-lowering drugs should have themselves monitored, as the drug may have a pronounced effect on blood sugar and A1C levels. Gastrointestinal aspects need to be considered since nausea, diarrhea, vomiting, and other gastrointestinal effects have been observed during the drug's clinical development.
Pancreatic or gallbladder problems should be discussed with your healthcare provider since this condition may play significance while considering incretin-based therapies. The issues of kidney or liver diseases, pregnancy, lactation, allergies, nutritional status, and co-medications should also be taken into account prior to treatment. Since the drug has not been officially approved, people should avoid using the medications from unidentified sources and retatrutide analogues from non-clinical sources.
Application/Consumption
Retatrutide has been researched for once-weekly subcutaneous administration. During the clinical trials, the method consists of dose titration and does not include immediate use of the maximum dose, since it helps tolerate the drug better as the body gets used to the treatment.
The drug is being researched in combination with healthy lifestyles, including proper nutrition and physical activity. The TRIUMPH-1 trial included obese and overweight people with comorbidities associated with their body weight; during the trial, they received retatrutide without diabetes as a part of a clinical trial. Retatrutide helped to lose weight significantly within 80 weeks.
Since retatrutide is still investigational, patients should avoid administering the drugs marketed on the Internet or by untrusted sources. According to Lilly, nobody should use any retatrutide-like product except in the Lilly-sponsored clinical trial.
Dosing information
Retatrutide does not currently have an approved clinical dose for routine patient treatment. Doses studied in Phase 3 trials have included 4 mg, 9 mg, and 12 mg once weekly, with gradual dose escalation used during treatment.
These doses represent clinical-trial regimens and should not be interpreted as approved prescribing recommendations. Final dosing recommendations, if retatrutide receives regulatory approval, will depend on regulatory review and the approved prescribing information.
Uses
Retatrutide is being investigated for:
- Obesity and overweight with weight-related complications
- Obesity with type 2 diabetes
- Weight management in people with severe obesity and cardiovascular disease
- Knee osteoarthritis associated with obesity
- Obstructive sleep apnea associated with obesity
- Improvement of blood glucose and A1C in type 2 diabetes
In the TRIUMPH Program of Phase 3, retatrutide showed significant weight loss among various cohorts. The TRIUMPH-1 trial was conducted in obesity without diabetes, the TRIUMPH-2 trial was conducted in obesity/overweight with type 2 diabetes, and the TRIUMPH-3 trial was conducted in severe obesity with known cardiovascular disease.
Further Phase 3 studies also focused on its effect on knee osteoarthritis pain and obstructive sleep apnea. Improved results for both were claimed by Lilly in its 2026 clinical trials.
But these are all investigational uses.
Retatrutide side effects
Since retatrutide is under clinical development, its safety profile is still under study. Adverse events found during Phase 3 clinical trials have involved mostly gastrointestinal disorders, which are common for other incretin-based medications as well. Nausea, diarrhea, vomiting, and other gastrointestinal symptoms can occur as side effects, especially when increasing the dose. According to Lilly, the most common adverse events seen in patients were similar to those seen in other incretins.
The severity and incidence of adverse events associated with gastrointestinal symptoms may vary according to different dose levels. Escalation of dose was included in the clinical trials to minimize tolerability issues. In clinical trials, patients will be observed for any adverse event.
Significant weight loss can lead to a change in nutritional needs and body composition. The person who receives experimental weight loss medication needs medical observation to maintain proper nutrition.
For patients with type 2 diabetes, retatrutide reduces A1C and blood glucose levels by a great margin. However, the drug needs to be monitored carefully since a change in the glucose level may necessitate a review of the patient's entire treatment regimen when used with other glucose-lowering drugs. In the TRANSCEND-T2D-1 study, retatrutide reduced A1C by up to 2.0% on average and reduced weight by up to 16.8% within 40 weeks.
The long-term safety data on retatrutide is still being developed. There are ongoing trials to determine its cardiovascular effects, metabolic effects, tolerability, and other possible adverse reactions. It is therefore not appropriate to equate the investigational safety information to the established safety information of an approved drug.
Severe and persistent cases of vomiting, diarrhea, dehydration, severe abdominal pain, blood glucose alterations, and any other adverse reactions should be attended to by medical personnel in case they occur in a clinical trial. The adverse events should be reported to the clinical trial medical personnel as per the protocol of the study.
It should be noted that retatrutide should not be confused with approved GLP-1 or dual GIP/GLP-1 drugs. Although it shares some biological pathways with these medicines, retatrutide also activates the glucagon receptor, making it a triple receptor agonist. Its clinical benefits and risks are therefore being evaluated independently through its Phase 3 development program.
Key insight:
In December 2025, Eli Lilly and Company announced positive topline results from the Phase 3 TRIUMPH-4 clinical trial, which evaluated the safety and efficacy of the two highest investigational doses of retatrutide, a first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist as an adjunct to a healthy diet and physical activity in adults without diabetes who had obesity or overweight and knee osteoarthritis.
